Hematological Changes in Patients Undergoing Diverse Anticancer Chemotherapy Regimens
DOI:
https://doi.org/10.60988/p.v38i1.226Keywords:
Blood indices, Anticancer, Platinum, Anthracyclines, TaxaneAbstract
Background: The hematological adverse effects linked to anticancer therapy is collectively challenging in clinical settings. Focused research directed to identify the hematological changes associated with each regiment protocols might help in appropriate decision for anticancer combination selection based on patient status. Aim of the study: We sought to map the hematological status associated with each treatment regimen currently used in clinical settings. Methods: To do so, blood samples were collected from cancer patients under current therapeutic protocols. Hemoglobin (Hb), white blood cells (WBCs), platelet (PLT), and lymphocyte (LYM) count were analyzed by Boule hematology analyzer machine. The treatment regimen were grouped based on the combination chemotherapy used, including platinum-based regimen (PBR), targeted therapy regimen (TTR), anthracycline-based regimen (ABR), taxane-based regimen (TBR), antimetabolite regimen (AmR), and immunotherapy regimen (ITR). Results: The most common type of cancer patients participated in the present study were breast cancer (33%). Lowest WBC count were associated with ovarian cancer (5.7±1.3 ×10³/μL) followed by lung cancer (6.9±2.1 ×10³/μL). The most common used treatment regimen was PBR (30%) followed by TTR (25%). The lowest WBC count were associated with ITR (6±1.9 ×10³/μL) and PBR(6.1±3.2 ×10³/μL). The lowest Hb level was associated with PBR (10.9±1.3 g/dL). The lowest PLT coumt were associated with PBR (245±121 ×10³/μL) and ABR (222±89 ×10³/μL). LYM were selectively reduced in AmR (1.3±0.5 ×10³/μL) and PBR (1.6±0.4 ×10³/μL) compared to other regimens. Conclusion: The hematological changes were greatly associated with conventional classical therapy of either PBR or TTR rather than the newly introduced AmR or ITR. Ovarian and lung cancer were mostly associated with hematological disturbances.
References
1. Aleem, E. & Arceci, R. J. Targeting cell cycle regulators in hematologic malignancies. Front. Cell Dev. Biol. 3, 1–22 (2015).
2. Crisci, S. et al. Overview of current targeted anti-cancer drugs for therapy in onco-hematology. Med. 55, 1–28 (2019).
3. Plackoska, V., Shaban, D. & Nijnik, A. Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression. Front. Immunol. 13, 1–16 (2022).
4. Popovici, D. et al. Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer. Exp. Ther. Med. 22, 1–8 (2021).
5. Kuter, D. J. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica 107, 1243–1263 (2022).
6. Passardi, A. et al. Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results. Oncologist 22, 886-e79 (2017).
7. Collado, M. C., Grześkowiak, Ł. & Salminen, S. Probiotic Strains and Their Combination Inhibit In Vitro Adhesion of Pathogens to Pig Intestinal Mucosa. Curr. Microbiol. 55, 260–265 (2007).
8. Stinchcombe, T. E., Borghaei, H., Barker, S. S., Treat, J. A. & Obasaju, C. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non–Small-Cell Lung Cancer. Clin. Lung Cancer 17, 1–9 (2016).
9. Bewersdorf, J. P. & Zeidan, A. M. Risk-adapted, individualized treatment strategies of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Cancers (Basel). 13, (2021).
10. Cotorogea-Simion, M. et al. What Is Different in Acute Hematologic Malignancy-Associated ARDS? An Overview of the Literature. Med. 58, 1–17 (2022).
11. Azzalini, E. et al. Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers. Gynecol. Oncol. 163, 498–505 (2021).
12. Kim, S. R. et al. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. Gynecol. Oncol. 158, 3–11 (2020).
13. Tanigawa, T. et al. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079). Gynecol. Oncol. 165, 413–419 (2022).
14. Molica, S. Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints. Expert Rev. Hematol. 17, 279–285 (2024).
15. Wais, V., Bunjes, D., Kuchenbauer, F. & Sorror, M. L. Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes. Expert Rev. Hematol. 11, 805–816 (2018).
16. Dai, D. et al. Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer. Front. Oncol. 11, 1–16 (2021).
17. Schmied, L., Höglund, P. & Meinke, S. Platelet-Mediated Protection of Cancer Cells From Immune Surveillance – Possible Implications for Cancer Immunotherapy. Front. Immunol. 12, 1–7 (2021).
18. Al-Danakh, A. et al. Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients. Front. Immunol. 15, 1–21 (2024).
19. Wang, X., Yang, J., Zhang, J. & Yang, H. Polypharmacy driven synergistic toxicities in elderly breast cancer chemotherapy drug management and adverse drug reactions: a mini review. Front. Pharmacol. 16, 1–7 (2025).
20. Liu, W., Wang, Y., Luo, J., Yuan, H. & Luo, Z. Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis. Front. Oncol. 9, 1573 (2019).
21. Crawford, J., Herndon, D., Gmitter, K. & Weiss, J. The impact of myelosuppression on quality of life of patients treated with chemotherapy. Futur. Oncol. 20, 1515–1530 (2024).
22. Rottenberg, S., Disler, C. & Perego, P. The rediscovery of platinum-based cancer therapy. Nat. Rev. Cancer 21, 37–50 (2021).
23. Harding, J. J. et al. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. Cancer Chemother. Pharmacol. 82, 429–440 (2018).
24. Drew, Y., Zenke, F. T. & Curtin, N. J. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat. Rev. Drug Discov. 24, 19–39 (2025).
25. Rocca, C., Pasqua, T., Cerra, M. C. & Angelone, T. Cardiac Damage in Anthracyclines Therapy: Focus on Oxidative Stress and Inflammation. Antioxidants & Redox Signal. 32, 1081–1097 (2020).
26. Zhou, X. et al. Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients. BMC Cancer 23, 976 (2023).
27. Chen, P. et al. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer. Adv. Sci. 8, 1–19 (2021).
28. Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M. S. & Catalano, A. Targeting Breast Cancer: An Overlook on Current Strategies. Int. J. Mol. Sci. 24, (2023).
29. Zhang, X. et al. Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Front. Immunol. 16, 1–20 (2025).
30. Yu, Q. et al. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility. J. Interv. Med. 6, 187–193 (2023).
31. Kubli, S. P., Berger, T., Araujo, D. V, Siu, L. L. & Mak, T. W. Beyond immune checkpoint blockade: emerging immunological strategies. Nat. Rev. Drug Discov. 20, 899–919 (2021).
32. Kanda, Y., Okazaki, T. & Katakai, T. Motility dynamics of T cells in tumor-draining lymph nodes: A rational indicator of antitumor response and immune checkpoint blockade. Cancers (Basel). 13, 1–18 (2021).
33. Pesce, S. et al. Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes. Cancers (Basel). 12, 1–25 (2020).
34. Li, R. et al. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: Results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. Pulm. Pharmacol. Ther. 25, 364–370 (2012).
